"The board is satisfied that there are no negative issues and trading remains in line with board expectations," the company said in a short statement.
Shares in the company were trading 8.6% lower at
Fri, 16th Mar 2018 16:21
"The board is satisfied that there are no negative issues and trading remains in line with board expectations," the company said in a short statement.
Shares in the company were trading 8.6% lower at
Regenerative medical devices group Tissue Regenix has received approval for DermaPure(R) reimbursement from two further administrators of the Medicare health insurance programme in the US. The approval from the Noridian Healthcare Solutions and Palmetto GBA Medicare administrators means that DermaPu
Read more